prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, Specimen #: Race WHITE. Physician (s) : SPECIMEN: A: SENTINEL NODE RIGHT BREAST B: RIGHT BREAST TISSUE. FINAL DIAGNOSIS: A. SENTINEL NODE, RIGHT, AXILLARY: - ONE (1) LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA BY H&E AND. IMMUNOHISTOCHEMISTRY. B. BREAST, RIGHT, NEEDLE-LOCALIZED EXCISION: TUMOR TYPE: INFILTRATING DUCTAL CARCINOMA, NOS, MULTIFOCAL. NOTTINGHAM GRADE: III/III (G3). NOTTINGHAM SCORE: 8/9. (Tubules= 3, Nuclei= 3, Mitoses= 2; mitotic count 13 per 10 HPF at. 40x power - field diameter = 0.63 mm). TUMOR SIZE (greatest dimension, measured grossly) : MASS #1: 1.0 CM. MASS #2: 0.5 CM. MASS #3 : 1.2 CM. TUMOR NECROSIS: PRESENT. MICROCALCIFICATIONS: PRESENT ASSOCIATED WITH CARCINOMA AND IN THE. MEDIA OF VESSELS (MEDIAL CALCIFIC SCLEROSIS) . VENOUS / LYMPHATIC INVASION: NOT IDENTIFIED. MARGINS INVASIVE (B7) AND IN SITU (B4, 7) CARCINOMA PRESENT LESS THAN. 0.1 CM FROM THE MEDIAL MARGIN (YELLOW). INTRADUCTAL COMPONENT: DUCTAL CARCINOMA IN SITU, NUCLEAR GRADE 3. (SOLID AND COMEDO TYPES). LYMPH NODES: SEE SPECIMEN "A". ESTROGEN RECEPTORS: : POSITIVE (95%). PROGESTERONE RECEPTORS: POSITIVE (95%). HER 2 NEU by IHC: NEGATIVE (1+). PATHOLOGIC STAGE: pT1c NO MX. ADDITIONAL PATHOLOGIC CHANGES: : FIBROCYSTIC CHANGES, MAMMOMARK. IDENTIFIED. COMMENT: Three clearly separate tumor foci have been identified grossly. and on the accompanying specimen radiograph, favoring the designation of. 'multifocal' rather than one large tumor. Specimen # : FINAL DIAGNOSIS (continued) : CLINICAL DIAGNOSIS AND HISTORY: year old female undergoing needle localized lumpectomy of the right. breast with sentinel node biopsy. GROSS DESCRIPTION: A. Received fresh, labeled with the patient's name,. designated "SENTINEL NODE RIGHT BREAST" is a 2.5 x 2.0 x 1.0 cm irregular. portion. of soft tissue. Sectioning reveals a single, pink-yellow, lymph. node measuring 1.5 x 0.5 x 0.3 cm. The lymph node is bisected. A matched. section of the specimen is submitted in cassette A1 is submitted in. for the CBCP protocol. The specimen is entirely submitted as follows: Cassette Key: A1: Lymph node. A2: Adipose tissue. B. Received fresh, labeled with the patient's name,. designated "RIGHT BREAST TISSUE" is an irregular portion of soft tissue. oriented as follows: short stitch is superior aspect, long stitch is. lateral aspect, and double stitch is the deep aspect. The specimen. measures 8.5 cm from medial to lateral, 8.5 cm from superior to inferior,. and 2.5 cm from anterior to posterior. The specimen is received with an. accompanying radiograph, and two embedded localization wires. The. specimen is inked as follows superior aspect is inked in blue, inferior. aspect is inked in green, the medial aspect is inked in yellow, the. lateral aspect is inked in red, the anterior aspect is inked in orange,. and the posterior aspect is inked in black. Serial sectioning reveals. three fairly well defined, pink-white masses. Mass #1 measures 1.0 x 0.7. x. 0.5. cm and is located 0.7 cm from the deep margin. Mass #2 measures 0.5. x 0.3 x 0.3 cm, and is located 0.5 cm anterior to mass #1 in approximately. the same plane of tissue, and coming to within 0.2 cm of the anterior and. lateral margins. Mass #3 measures 1.2 x 1.0 x 0.6 cm, and is located 1.0. cm medial to mass #1 and mass #2 coming to within 0.2 cm of the anterior. margin. The remainder of the specimen is composed of lobulated,. yellow-tan, adipose tissue admixed with minimal fibrous tissue. No. Specimen #: GROSS DESCRIPTION (continued). additional lesions are identified. At the time of processing, the. specimen will have spent 51 hours fixing in formalin. The specimen is. submitted as follows: Cassette Key. B1: Representative section of mass #1. B2: : Margins of specimen submitted in cassette B1. B3-B4 - Representative sections from mass #2. B5 : Normal appearing breast tissue adjacent to cassette B4. B6: Representative section of mass #3 with nearest margin. B7: Representative section of mass #3 with nearest margin. B8-B9: - Additional margins from mass #1. B11-B14 : Additional margins from mass #2. B15: Area of fibrous tissue medial to mass #3. Matched sections of specimen is submitted in cassettes B1, B5, and B7 are. submitted in. for the clinical breast care project protocol. Z.

expanded version (tokens=1582) : 
 Histological Classification: Infiltrating Ductal Carcinoma (IDC) with Ductal Carcinoma in situ (DCIS) component

Subtype: Luminal A

Necrosis: Present

Tumor Infiltrating Lymphocytes: Not identified

Histological Grade: Nottingham Grade III/III (G3)

Nuclear Grade: 3

Lymphovascular Invasion: Not identified

Calcification: Present, associated with carcinoma and in the media of vessels (medial calcific sclerosis)

Receptor Status: Estrogen Receptors (ER) and Progesterone Receptors (PR) positive (95%), HER2 negative (1+)

Ancillary Testing Results: Fibrocystic changes and mammoMark identified

Additional Information: The patient underwent a needle-localized lumpectomy of the right breast with sentinel node biopsy. Three separate tumor foci were identified. The final pathological stage was pT1c NO MX. Representative sections of the mass and normal adjacent breast tissue were submitted for the clinical breast care project protocol.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1748) : 
 The patient has Luminal A subtype Infiltrating Ductal Carcinoma with DCIS component, graded as Nottingham Grade III/III (G3), and tumor size measuring 1.0 cm, 0.5 cm, and 1.2 cm grossly. Necrosis was present, but lymphovascular invasion was not identified. ER/PR were positive (95%), HER2 negative (1+). Fibrocystic changes and mammoMark were identified and the final pathological stage was pT1c NO MX. Three separate tumor foci were identified.

